| Literature DB >> 30093786 |
Takuma Tsuchiya1,2, Aki Kijima1, Yuji Ishii1, Shinji Takasu1, Yuh Yokoo1, Akiyoshi Nishikawa1, Tokuma Yanai2, Takashi Umemura1,3.
Abstract
Despite its antimicrobial activity, nitrofurantoin (NFT) is a renal carcinogen in rats. Oxidative stress induced by reduction of the nitro group of NFT may contribute to its genotoxicity. This is supported by our recent results indicating that the structure of the nitrofuran plays a key role in NFT-induced genotoxicity, and oxidative DNA damage is involved in renal carcinogenesis. Nuclear factor erythroid 2-related factor 2 (NRF2) regulates cellular responses to oxidative stress. To clarify the role of oxidative stress in the chemical structure-related genotoxic mechanism of NFT, we performed reporter gene mutation assays for NFT and 5-nitro-2-furaldehyde (NFA) using Nrf2-proficient and Nrf2-deficient gpt delta mice. NFT administration for 13 weeks resulted in a significant increase in 8-hydroxydeoxyguanosine (8-OHdG; a marker of oxidative stress) and gpt mutant frequency only in the kidneys of Nrf2-/- mice. The mutation spectrum, characterized by increased substitutions at guanine bases, suggested that oxidative stress is involved in NFT-induced genotoxicity. However, NFA did not increase the mutation frequency in the kidneys, despite the increased 8-OHdG in NFA-treated Nrf2-/- mice. Thus, it is unlikely that oxidative stress is involved in the genotoxic mechanism of NFA. These results imply that nitro reduction plays a key role in the genotoxicity of NFT, but the lack of a role of oxidative stress in the genotoxicity of NFA indicates a potential role of side chain interactions in oxidative stress caused by nitro reduction. These findings provide a basis for the development of safe nitrofurans.Entities:
Keywords: NRF2; in vivo mutagenicity; kidney; nitrofurantoin; oxidative stress
Year: 2018 PMID: 30093786 PMCID: PMC6077154 DOI: 10.1293/tox.2018-0014
Source DB: PubMed Journal: J Toxicol Pathol ISSN: 0914-9198 Impact factor: 1.628
Fig. 1.Chemical structures of NFT and NFA.
Fig. 2.Growth curves for Nrf2+/+ (left panel) and Nrf2−/− (right panel) mice treated with NFT or NFA for 13 weeks. For both genotypes, there were no significant differences in body weight between treated and untreated mice.
Final Body and Kidney Weights of Male Nrf2+/+ or Nrf2−/−gpt Delta Mice Treated with NFT or NFA for 13 Weeks
Fig. 3.Changes in the Nrf2-target gene Nqo1 at the mRNA (A) and protein levels (B). (A) Data are presented as means ± SD. †mRNA expression levels in the Nrf2−/− control group were significantly different (P<0.05) from levels in the Nrf2+/+ control group by Student’s t-test.
Fig. 4.8-OHdG levels in the kidneys of Nrf2+/+ or Nrf2−/−gpt delta mice treated with NFT or NFA for 13 weeks. Data are presented as means ± SD for 3 mice in the groups treated with other than 41 mg/kg NFA. In the 41 mg/kg NFA group, the data obtained from one mouse are presented. *Significantly different (P<0.05) from levels in the relative control group by Dunnett’s test.
Gpt Mutation Frequencies in Kidneys of Nrf2+/+ or Nrf2−/−gpt Delta Mice Treated with NFT or NFA for 13 Weeks
Mutation Spectra in the Kidneys of Nrf2+/+ gpt Delta Mice Treated with NFT or NFA for 13 Weeks
Mutation Spectra in the Kidneys of Nrf2−/− gpt Delta Mice Treated with NFT or NFA for 13 Weeks
Spi– Mutant Frequencies in Kidneys of Nrf2+/+ or Nrf2−/−gpt Delta Mice Treated with NFT or NFA for 13 Weeks